European CHMP recommends approval of hepatitis B surface antigen (Heplisav B) for immunisation against hepatitis B virus infection

Heplisav B induces specific humoral antibodies against hepatitis B surface antigen. Reported benefits include ability to induce protective levels of antibody after the second dose of the vaccine. It also contains an adjuvant, to improve and sustain production of antibodies.

Source:

European Medicines Agency